| Steatohepatitis: a tale of two “hits”? CP Day, OFW James Gastroenterology 114 (4), 842-845, 1998 | 6246 | 1998 |
| The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ... Hepatology 45 (4), 846-854, 2007 | 3483 | 2007 |
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease European Association for the Study of The Liver, ... Obesity facts 9 (2), 65-90, 2016 | 2533 | 2016 |
| Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease G Targher, CP Day, E Bonora New England Journal of Medicine 363 (14), 1341-1350, 2010 | 2346 | 2010 |
| QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. CP Day, JM McComb, RW Campbell Heart 63 (6), 342-344, 1990 | 2100 | 1990 |
| Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis QM Anstee, G Targher, CP Day Nature reviews Gastroenterology & hepatology 10 (6), 330-344, 2013 | 1958 | 2013 |
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications GP Aithal, CP Day, PJL Kesteven, AK Daly The Lancet 353 (9154), 717-719, 1999 | 1697 | 1999 |
| Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease L Miele, V Valenza, G La Torre, M Montalto, G Cammarota, R Ricci, ... Hepatology 49 (6), 1877-1887, 2009 | 1695 | 2009 |
| Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1600 | 2018 |
| Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients G Targher, L Bertolini, R Padovani, S Rodella, R Tessari, L Zenari, C Day, ... Diabetes care 30 (5), 1212-1218, 2007 | 1527 | 2007 |
| A position statement on NAFLD/NASH based on the EASL 2009 special conference V Ratziu, S Bellentani, H Cortez-Pinto, C Day, G Marchesini Journal of hepatology 53 (2), 372-384, 2010 | 1453 | 2010 |
| Mortality after surgery in Europe: a 7 day cohort study RM Pearse, RP Moreno, P Bauer, P Pelosi, P Metnitz, C Spies, B Vallet, ... The Lancet 380 (9847), 1059-1065, 2012 | 1425 | 2012 |
| The natural history of nonalcoholic fatty liver: a follow‐up study MR Teli, OFW James, AD Burt, MK Bennett, CP Day Hepatology 22 (6), 1714-1719, 1995 | 1271 | 1995 |
| Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee Journal of hepatology 62 (5), 1148-1155, 2015 | 1223 | 2015 |
| Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis AM Diehl, C Day New England Journal of Medicine 377 (21), 2063-2072, 2017 | 1211 | 2017 |
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ... Nature genetics 41 (7), 816-819, 2009 | 1172 | 2009 |
| Non-alcoholic fatty liver disease: the mist gradually clears NMW de Alwis, CP Day Journal of hepatology 48, S104-S112, 2008 | 1057 | 2008 |
| Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease S McPherson, SF Stewart, E Henderson, AD Burt, CP Day Gut 59 (9), 1265-1269, 2010 | 979 | 2010 |
| Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ... Hepatology 47 (2), 455-460, 2008 | 918 | 2008 |
| Nonalcoholic fatty liver disease EM Brunt, VWS Wong, V Nobili, CP Day, S Sookoian, JJ Maher, ... Nature reviews Disease primers 1 (1), 1-22, 2015 | 839 | 2015 |
